Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS002 in heterozygous familial hypercholesterolemia (HeFH)
CTR20212751Phase 3Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ongericimab in familial hypercholesterolemia (FH), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Nov 2021; status: completed.
02
Drugs
ongericimab
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on CTR20212751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212751.